February 13, 2015
1 min read
Save

CREDO-Kyoto: Better long-term outcomes with CABG vs. PCI, regardless of diabetes status

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

At 5 years, patients with and without diabetes who had three-vessel and/or left main disease had better rates of cardiac death, MI and coronary revascularization after CABG compared with PCI.

The multicenter Japanese CREDO-Kyoto PCI/CABG Registry Cohort-2 included 15,939 patients with first coronary revascularization. The current analysis focused on 3,982 patients with three-vessel and/or left main disease; 1,998 had diabetes (PCI, n = 1,065; CABG, n = 933) and 1,984 did not have diabetes (PCI, n = 1,123; CABG, n = 861).

At 5 years, the cumulative incidence of all-cause mortality was higher for patients who underwent PCI compared with CABG. Among patients without diabetes, the 5-year cumulative incidence rate was 19.8% after PCI vs. 16.2% after CABG (P = .01). Among patients with diabetes, the 5-year cumulative incidence rate was 22.9% after PCI vs. 19% after CABG (P = .046). When the researchers adjusted for confounding factors, the increased mortality risk after PCI remained significant among patients with diabetes (P = .04), but was no longer significant among patients without diabetes (P = .29).

Compared with CABG, PCI was associated with higher adjusted risks for cardiac death (HR = 1.45; 95% CI, 1-2.51), MI (HR = 2.31; 95% CI, 1.31-4.08) and any coronary revascularization (HR = 3.7; 95% CI, 2.91-4.69) among patients with diabetes. A similar trend was observed in favor of CABG in the patients without diabetes (cardiac death: HR = 1.59; 95% CI, 1.01-2.51; MI: HR = 2.16; 95% CI, 1.2-3.87; any coronary revascularization: HR = 3.3; 95% CI, 2.55-4.25).

The researchers found no interaction between diabetes status and the effect of PCI vs. CABG for any clinical outcome.

“We believe registry data [are] also important to elucidate the impact of CABG in large-volume, real-world diabetic patients,” the researchers wrote.

Disclosure: The researchers report no relevant financial disclosures.